Formulating a steadily raised theory of collaboration Expand cooperation when checking initial results
사진 확대 
사진 확대 Olyx CEO Lee Dong-ki gives a description of the main pipeline at the “R&D Day for the First Half of the Year 2025” in late May. News1
Olix, a bio company based on RNA interference (RNAi) technology, will join hands with global beauty company L’Oreal to jointly research and develop skin and hair regeneration. This contract formalizes the theory of cooperation that has been steadily raised in the industry, and is noteworthy in that it has even left open the possibility of technology transfer. However, the stock price declined due to the influence of expectations already reflected in the market.
Olyx announced on the 9th that it has signed an exclusive Scientific Collaboration with L’Oreal Group in France. Based on Olyx’s RNAi platform technology, the two companies plan to co-develop innovative solutions for skin and hair health, especially regeneration and longevity.
The contract is multi-level over the years, and Olyx has secured tens of billions of won in research and development funds. Although specific R&D tasks or amounts are private, the two companies have agreed to expand the scale of cooperation if initial results are confirmed.
“We are excited to partner with Olix, a world leader in RNA technology,” said L’Oreal Giib, global general director of Verrucci. “We expect new beauty solutions to be born at the point where science, biology, and technology meet.”
Lee Dong-ki, CEO of Olyx, said, “The collaboration with L’Oreal means global verification of Olyx technology,” and emphasized, “We will become a game changer in the skin and hair regeneration field by combining the capabilities of both companies.”
The contract was “predictable news” in the industry. Olyx already mentioned at the “R&D Day in the First Half of 2025” in late May that “a skin and hair regeneration partnership with global beauty companies is imminent.” Since then, expectations have been largely reflected in stock prices as the assumption that the collaboration target is L’Oreal has spread.
Orix shares are trading at 45,600 won on the day, down 7.22% from the previous day. On the surface, it is a good thing, but since the stock price has already more than quadrupled since the signing of the technology transfer contract with Lily in February, analysts say that profit-taking sales due to exposure to materials have poured out.
Apart from this collaboration, Olyx is also conducting clinical trials for its new drug candidate “OLX104C” targeting male alopecia. This drug is a mechanism that treats hair loss by inhibiting the expression of androgen receptors (AR), and has currently submitted a phase 1b and 2a clinical trial plan (IND) in Australia.
Some analysts say that this contract could be a positive turning point for Olyx’s mid- to long-term growth if it leads to technology transfer or commercialization partnerships, not just research cooperation. The market is paying attention to Olix’s move to expand its presence to the beauty and regenerative bio markets based on RNAi technology.